Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database

Gaetana Sterrantino, Mauro Zaccarelli, Antonio Di Biagio, Maria Luisa Biondi, Andrea Antinori, Giovanni Penco

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: We assessed the virological response of dual therapy with DRV/r, plus raltegravir, maraviroc or etravirine, in virological failure patients and in virologically suppressed patients collected in the Italian Antiretroviral Resistance Database (ARCA). Material and methods: The primary endpoint was the percentage of patients remaining free of virological failure (confirmed >50 copies/mL or any change in the regimen). Subjects had a resistance test and at least one follow-up visit. Observation was censored at last visit under dual therapy and survival analysis and proportional hazard models were used. Results: Sixty-seven percent of the 221 patients started DRV/r with RAL, 20.4 % with ETV, and 12.2 % with MAR; 31.2 % virological failures were observed. At survival analysis, the overall proportion of failure was 29.2 % at 1 year and 33.8 % at 2 years. The proportion of failure was lower in patients starting with undetectable vs. detectable viral load (13.3 and 25.2 % vs. 37.4 and 38.8 % at 1 and 2 years, respectively, p = 0.001 for both analyses) and in patients treated with DRV 600 BID vs. 800 QD (HR: 0.56, 95 % CI: 0.31–0.99, p 

Original languageEnglish
Pages (from-to)339-343
Number of pages5
JournalInfection
Volume43
Issue number3
DOIs
Publication statusPublished - Mar 28 2015

Fingerprint

HIV
Databases
etravirine
Survival Analysis
Therapeutics
Viral Load
Proportional Hazards Models
Darunavir
Observation

Keywords

  • Darunavir/r dual therapy
  • Etravirine
  • Maraviroc
  • Raltegravir
  • Switching strategies

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Darunavir-based dual therapy of treatment-experienced HIV-infected patients : analysis from a national multicenter database. / Sterrantino, Gaetana; Zaccarelli, Mauro; Di Biagio, Antonio; Biondi, Maria Luisa; Antinori, Andrea; Penco, Giovanni.

In: Infection, Vol. 43, No. 3, 28.03.2015, p. 339-343.

Research output: Contribution to journalArticle

Sterrantino, Gaetana ; Zaccarelli, Mauro ; Di Biagio, Antonio ; Biondi, Maria Luisa ; Antinori, Andrea ; Penco, Giovanni. / Darunavir-based dual therapy of treatment-experienced HIV-infected patients : analysis from a national multicenter database. In: Infection. 2015 ; Vol. 43, No. 3. pp. 339-343.
@article{898ad8ef31b74fdeb8043b3defa20bfb,
title = "Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database",
abstract = "Background: We assessed the virological response of dual therapy with DRV/r, plus raltegravir, maraviroc or etravirine, in virological failure patients and in virologically suppressed patients collected in the Italian Antiretroviral Resistance Database (ARCA). Material and methods: The primary endpoint was the percentage of patients remaining free of virological failure (confirmed >50 copies/mL or any change in the regimen). Subjects had a resistance test and at least one follow-up visit. Observation was censored at last visit under dual therapy and survival analysis and proportional hazard models were used. Results: Sixty-seven percent of the 221 patients started DRV/r with RAL, 20.4 {\%} with ETV, and 12.2 {\%} with MAR; 31.2 {\%} virological failures were observed. At survival analysis, the overall proportion of failure was 29.2 {\%} at 1 year and 33.8 {\%} at 2 years. The proportion of failure was lower in patients starting with undetectable vs. detectable viral load (13.3 and 25.2 {\%} vs. 37.4 and 38.8 {\%} at 1 and 2 years, respectively, p = 0.001 for both analyses) and in patients treated with DRV 600 BID vs. 800 QD (HR: 0.56, 95 {\%} CI: 0.31–0.99, p ",
keywords = "Darunavir/r dual therapy, Etravirine, Maraviroc, Raltegravir, Switching strategies",
author = "Gaetana Sterrantino and Mauro Zaccarelli and {Di Biagio}, Antonio and Biondi, {Maria Luisa} and Andrea Antinori and Giovanni Penco",
year = "2015",
month = "3",
day = "28",
doi = "10.1007/s15010-015-0764-z",
language = "English",
volume = "43",
pages = "339--343",
journal = "Infection",
issn = "0300-8126",
publisher = "Urban und Vogel GmbH",
number = "3",

}

TY - JOUR

T1 - Darunavir-based dual therapy of treatment-experienced HIV-infected patients

T2 - analysis from a national multicenter database

AU - Sterrantino, Gaetana

AU - Zaccarelli, Mauro

AU - Di Biagio, Antonio

AU - Biondi, Maria Luisa

AU - Antinori, Andrea

AU - Penco, Giovanni

PY - 2015/3/28

Y1 - 2015/3/28

N2 - Background: We assessed the virological response of dual therapy with DRV/r, plus raltegravir, maraviroc or etravirine, in virological failure patients and in virologically suppressed patients collected in the Italian Antiretroviral Resistance Database (ARCA). Material and methods: The primary endpoint was the percentage of patients remaining free of virological failure (confirmed >50 copies/mL or any change in the regimen). Subjects had a resistance test and at least one follow-up visit. Observation was censored at last visit under dual therapy and survival analysis and proportional hazard models were used. Results: Sixty-seven percent of the 221 patients started DRV/r with RAL, 20.4 % with ETV, and 12.2 % with MAR; 31.2 % virological failures were observed. At survival analysis, the overall proportion of failure was 29.2 % at 1 year and 33.8 % at 2 years. The proportion of failure was lower in patients starting with undetectable vs. detectable viral load (13.3 and 25.2 % vs. 37.4 and 38.8 % at 1 and 2 years, respectively, p = 0.001 for both analyses) and in patients treated with DRV 600 BID vs. 800 QD (HR: 0.56, 95 % CI: 0.31–0.99, p 

AB - Background: We assessed the virological response of dual therapy with DRV/r, plus raltegravir, maraviroc or etravirine, in virological failure patients and in virologically suppressed patients collected in the Italian Antiretroviral Resistance Database (ARCA). Material and methods: The primary endpoint was the percentage of patients remaining free of virological failure (confirmed >50 copies/mL or any change in the regimen). Subjects had a resistance test and at least one follow-up visit. Observation was censored at last visit under dual therapy and survival analysis and proportional hazard models were used. Results: Sixty-seven percent of the 221 patients started DRV/r with RAL, 20.4 % with ETV, and 12.2 % with MAR; 31.2 % virological failures were observed. At survival analysis, the overall proportion of failure was 29.2 % at 1 year and 33.8 % at 2 years. The proportion of failure was lower in patients starting with undetectable vs. detectable viral load (13.3 and 25.2 % vs. 37.4 and 38.8 % at 1 and 2 years, respectively, p = 0.001 for both analyses) and in patients treated with DRV 600 BID vs. 800 QD (HR: 0.56, 95 % CI: 0.31–0.99, p 

KW - Darunavir/r dual therapy

KW - Etravirine

KW - Maraviroc

KW - Raltegravir

KW - Switching strategies

UR - http://www.scopus.com/inward/record.url?scp=84930275717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930275717&partnerID=8YFLogxK

U2 - 10.1007/s15010-015-0764-z

DO - 10.1007/s15010-015-0764-z

M3 - Article

C2 - 25821204

AN - SCOPUS:84930275717

VL - 43

SP - 339

EP - 343

JO - Infection

JF - Infection

SN - 0300-8126

IS - 3

ER -